HCW Biologics Inc. announced that at its 2026 Annual Meeting of Stockholders on June 15, 2026, shareholders approved several key proposals. These include authorizing a reverse stock split to maintain its Nasdaq listing, approving the issuance of shares related to a recent warrant offering, and sanctioning the repricing of certain existing warrants.
Key Details
- Reverse Stock Split: Stockholders authorized the company to implement a reverse stock split at a ratio between 1-for-5 and 1-for-20, as needed to remain compliant with Nasdaq listing requirements.
- Warrant Repricing: Approved the repricing of warrants (issued Nov. 2025) to purchase up to 3,020,410 shares, reducing the exercise price to $0.6055 per share.
- Warrant Issuance: Approved the potential issuance of shares upon the exercise of up to 2,477,292 warrants related to the company's February 17, 2026 public offering.
- Director Election: Lisa M. Giles and Rick S. Greene were elected as Class II directors to serve a three-year term.